Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.85 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19230849 | 0.92 | KCNH2 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL19230850 | 0.91 | KCNH2 (0.85) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181658 | 0.89 | HDAC2 (0.82) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL19230845 | 0.86 | KCNH2 (0.77) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL19230847 | 0.84 | KCNH2 (0.82) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL15922983 | 0.84 | HDAC3 (1.00) | KCNH2HDAC2HDAC3HDAC1 | |
| SCHEMBL20181490 | 0.83 | KCNH2 (0.77) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL20181513 | 0.83 | HDAC2 (1.00) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL20181478 | 0.82 | HDAC2 (0.67) | KCNH2HDAC2HDAC3HDAC1CYP1A2 | |
| SCHEMBL17572848 | 0.80 | KCNH2 (0.79) | KCNH2HDAC2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC | 2017-08-24 | — | — | US | disclosed |
| WO-2017136451-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | REGENACY PHARMACEUTICALS, LLC (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240535-A1 | HDAC1/2 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR COGNITIVE DISORDERS | HDAC1, HDAC2, HDAC11 | KCNH2 4701/4885HDAC2 2/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.